



✓ 1645#
PATENT
Customer No. 22,852
Attorney Docket No. 1246-134

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Ahmed Jehanli et al.

Application No.: 09/918,637

Filed: August 1, 2001

For: Medical Kit

)
)
) Group Art Unit: 1645
)
) Examiner: Jana A. Hines
)
)
)

RECEIVED

APR 14 2003

Commissioner for Patents
Washington, DC 20231

TECH CENTER 1600/2900

Sir:

TRANSMITTAL LETTER

Enclosed is a reply to the Office Action of December 10, 2002. The item(s) checked below are appropriate:

- ☒ Applicant(s) hereby petition(s) for a three month(s) extension of time to respond to the above Office Action. The fee of \$465 (small entity) for the Extension is enclosed.

The claims are calculated below:

	Claims Remaining After Amendment		Highest Number Previously Paid	Present Extra	Rate	Additional Fee
Total	23	-	23		x \$ 18	
Indep.	1	-	3		x \$.84	
<input type="checkbox"/> First Presentation of Multiple Dep. Claim(s)					+\$280	
Subtotal						\$
Reduction by 1/2 if small entity						-
TOTAL						\$

- ☐ A fee of \$_____ to cover the cost of the additional claims added by this reply is enclosed.
- ☐ A fee of \$_____ to cover _____ is enclosed.
- ☒ A check for \$465 to cover the above fee(s) is enclosed.

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Dated: April 10, 2003

By: 
Arthur S. Garrett

Reg. No. 20,338

12448_1.DOC

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com



PATENT
Customer No. 22,852
Attorney Docket No. 1246-134

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Ahmed Jehanli et al.

Application No.: 09/918,637

Filed: August 1, 2001

For: Medical Kit

Commissioner for Patents
Washington, DC 20231

)
)
) Group Art Unit: 1645
)
) Examiner: Jana A. Hines
)
)
)

RECEIVED

APR 14 2003

TECH CENTER 1600/2900

Sir:

RESPONSE

In response to the Office Action of December 10, 2002, applicants elect the following:

With respect to claim 2, applicants elect protein as the subgeneric species. From this subgeneric species, applicants elect rabbit serum albumin.

With respect to claim 6, applicants elect antihypertensive as the subgeneric species. From this subgeneric species, applicants elect lisinopril.

It is understood that the claims will only have to be restricted to the elected species in the event a generic claim is not found to be allowable.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

04/11/2003 STEUMEL1 00000054 09918637

01 FC:2253

465.00 DP


Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: April 10, 2008

By:


Arthur S. Garrett
Reg. No. 20,338

12458_1.DOC

RECEIVED

APR 14 2003

TECH CENTER 1600/2900

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com